923,552 Shares in Zimmer Biomet Holdings, Inc. $ZBH Acquired by Deutsche Bank AG
Deutsche Bank AG recently acquired a significant new stake of 923,552 shares in Zimmer Biomet Holdings, Inc. (NYSE:ZBH), valued at approximately $79.5 million. This acquisition makes Deutsche Bank AG one of many institutional investors increasing or initiating positions in the medical equipment provider. Zimmer Biomet's stock currently holds a "Hold" consensus rating from analysts, with an average target price of $104.42, following recent upgrades and price target increases from several firms.
BlackRock Inc. Makes New $1.34 Billion Investment in Zimmer Biomet Holdings, Inc. $ZBH
BlackRock Inc. has acquired a new position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH), purchasing over 15.6 million shares valued at approximately $1.34 billion, representing about 8.07% ownership. This comes as several other institutional investors also adjusted their stakes in the medical equipment provider, while an insider recently sold 5,000 shares. Zimmer Biomet reported strong quarterly earnings, beating analyst estimates, and has received varied ratings from equities analysts, with a consensus "Hold" rating.
ZBH5302814 Bond Profile — Key Metrics
This article provides key metrics for the Zimmer Biomet Holdings, Inc. bond ZBH5302814, detailing its coupon rate, issue and maturity dates, outstanding amount, and face value. It also includes a description of Zimmer Biomet Holdings, Inc.'s business, which involves the design, manufacture, and marketing of orthopedic reconstructive products across various global segments. The bond has a 2.6% coupon and matures on November 24, 2031.
Zimmer Biomet Holdings Inc. stock outperforms competitors despite losses on the day
Zimmer Biomet Holdings Inc. (ZBH) stock experienced a 1.76% drop to $98.97, breaking a two-day winning streak, amidst a general market decline with the S&P 500 Index and Dow Jones Industrial Average also falling. Despite its own losses, Zimmer Biomet's stock performed better than the overall market. The article highlights the stock's performance relative to its competitors and the broader market indices on a challenging trading day.
Is Zimmer Biomet Stock Worth Retaining in Your Portfolio Now?
Zimmer Biomet (ZBH) appears well-positioned for future growth due to strong orthopedic procedure demand and increasing adoption of its Z1, HAMMR, and OrthoGrid products. However, the company faces challenges from intense competition and a significant debt burden, leading to its current Zacks Rank #3 (Hold) status. Despite these concerns, ZBH has consistently beaten earnings estimates and analysts have slightly raised EPS estimates for 2026.
United Bank Invests $1.26 Million in Zimmer Biomet Holdings, Inc. $ZBH
United Bank recently acquired a new stake of 14,621 shares in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) valued at approximately $1.26 million during the second quarter. Other institutional investors have also adjusted their positions in ZBH, with 88.89% of the stock owned by institutions and hedge funds. The medical equipment provider recently reported strong Q2 earnings, beating analyst estimates, and announced a quarterly dividend.
482,055 Shares in Zimmer Biomet Holdings, Inc. $ZBH Acquired by Mitsubishi UFJ Asset Management Co. Ltd.
Mitsubishi UFJ Asset Management Co. Ltd. recently acquired 482,055 shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH), valued at approximately $41.5 million, giving them a 0.25% stake in the company. Zimmer Biomet exceeded its quarterly earnings expectations, reporting $2.07 EPS on $2.18 billion in revenue, and maintained its 2026 EPS guidance. The stock currently holds a "Hold" consensus rating from analysts with an average price target of $104.42, and offers a quarterly dividend of $0.24 per share.
DCF Advisers LLC Purchases Shares of 30,500 Zimmer Biomet Holdings, Inc. $ZBH
DCF Advisers LLC recently acquired 30,500 shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the second quarter, a stake valued at approximately $2.63 million. This purchase is part of a broader trend of institutional investment, with such entities collectively owning 88.89% of the company. Zimmer Biomet reported strong quarterly earnings, surpassing analyst estimates with $2.07 EPS and $2.18 billion in revenue, and analysts currently maintain a consensus "Hold" rating with an average price target of $104.42.
Zimmer Biomet (ZBH) Stock Still Looks Discounted After a 28% Five Year Slide
Zimmer Biomet Holdings (ZBH) has experienced a 27.9% decline in its share price over the last five years, yet Simply Wall St's analysis suggests the stock remains undervalued. Despite weak long-term returns, ZBH trades at a P/E of 23.8x, below the Medical Equipment industry average of 28.0x and its peer group average of 36.9x, suggesting a market discount. The company's ongoing restructuring, including a shift to a dedicated sales force, presents both potential for stronger growth and execution risks that investors need to consider.
1,681,360 Shares in Zimmer Biomet Holdings, Inc. $ZBH Purchased by Equity Investment Corp
Equity Investment Corp recently acquired 1,681,360 shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) valued at approximately $144.75 million, making it their 11th largest holding. Other institutional investors also adjusted their positions in the medical equipment provider, which saw its stock open at $99.31 with a market cap of $18.94 billion. The company recently declared a quarterly dividend of $0.24 and analysts have a "Hold" consensus rating with an average target price of $104.42.
First National Bank of Omaha Invests $12.55 Million in Zimmer Biomet Holdings, Inc. $ZBH
First National Bank of Omaha has invested approximately $12.55 million in Zimmer Biomet Holdings, Inc. by acquiring 140,635 shares, representing a 0.07% stake. Zimmer Biomet recently exceeded Q2 earnings expectations with $2.07 EPS and $2.18 billion in revenue, while maintaining its fiscal 2026 EPS guidance. The medical equipment provider currently trades at $99.31, offers a quarterly dividend of $0.24, and has an average analyst "Hold" rating with a target price of $104.42.
What Enovis (ENOV)'s Narrowing Losses And Reaffirmed 2026 Outlook Means For Shareholders
Enovis Corporation reported Q2 2026 results with reduced net losses and reaffirmed its 2026 revenue guidance of US$2.31 billion to US$2.37 billion, including 4–6% organic growth. This indicates management's confidence in the company's trajectory, despite ongoing losses. The investment narrative emphasizes consistent profitability from its medtech portfolio, with margin improvement and successful integration of acquisitions being key near-term catalysts and risks.
Smith+Nephew, Imperial College London Launch Surgical Robotics Innovation Center
Smith+Nephew has partnered with Imperial College London to open a new Surgical Robotics Innovation Center. This five-year collaboration aims to accelerate the translation of academic research into clinical applications for orthopedic robotic surgery, focusing on less invasive procedures and improved patient outcomes. The partnership represents a new model for medtech innovation by embedding industry engineers directly within the university's Hamlyn Centre to co-develop and commercialize breakthrough technologies more rapidly.
Is ISRG's Software Strategy Becoming as Important as Its Robots?
Intuitive Surgical (ISRG) is increasingly relying on its software strategy to enhance the value of its da Vinci 5 robotic platform, extending its competitive moat beyond just hardware. The company is implementing numerous software updates and integrated offerings like My Intuitive+ to improve usability, efficiency, and clinical capabilities, fostering customer loyalty and supporting its recurring-revenue model. This approach is also being mirrored by competitors like Stryker and Zimmer Biomet, who are embedding digital capabilities into their robotic ecosystems to differentiate their solutions and strengthen market stickiness.
Grandfield & Dodd LLC Buys New Position in Zimmer Biomet Holdings, Inc. $ZBH
Grandfield & Dodd LLC has acquired a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH), purchasing 11,539 shares valued at approximately $993,000. This move is part of broader institutional investor activity, with several other firms also adjusting their positions in the medical equipment provider. Analysts currently have a mixed outlook on Zimmer Biomet, with a consensus "Hold" rating and an average price target of $104.42.
J.P. Morgan Maintains Zimmer Biomet Holdings(ZBH.US) With Hold Rating, Raises Target Price to $117
J.P. Morgan has reiterated its Hold rating on Zimmer Biomet Holdings (ZBH.US) and increased its target price for the stock to $117. This indicates a maintained neutral outlook with a slightly more optimistic valuation for the company's shares.
Zimmer Biomet Holdings Inc. stock underperforms Monday when compared to competitors
Shares of Zimmer Biomet Holdings Inc. (ZBH) fell 2.43% on Monday, closing at $98.20. This underperformance occurred during a generally poor trading session for the stock market, with both the S&P 500 Index and Dow Jones Industrial Average also declining. The stock's drop ended a three-day winning streak.
Zimmer Biomet Holdings, Inc. (ZBH) Stock Analysis: Navigating a 6.88% Potential Upside in the Medical Device Sector
Zimmer Biomet Holdings, Inc. (ZBH) is a major player in the medical devices sector, known for its orthopedic reconstructive products and digital technologies. The company shows financial strength with a 4.80% revenue growth, a 0.95% dividend yield, and a potential 6.88% upside based on analyst targets. Its focus on robotic technologies like the ROSA Robot and ZBEdge Platform positions it well for future growth in healthcare.
297,894 Shares in Zimmer Biomet Holdings, Inc. $ZBH Bought by Alberta Investment Management Corp
Alberta Investment Management Corp recently purchased 297,894 shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) valued at approximately $25.65 million, establishing a new position in the medical equipment provider. Other institutional investors also adjusted their holdings in ZBH, which currently has a "Hold" rating from analysts with an average target price of $104.42. The article also notes recent insider selling and provides financial performance metrics and dividend information for Zimmer Biomet.
Zimmer Biomet Holdings (ZBH) Could Be 2% Undervalued As Q2 Beat Lifts The Story
Zimmer Biomet Holdings (ZBH) saw its shares gain momentum after a strong Q2 earnings report, exceeding Wall Street expectations. The company's focus on robotics, digital tools, and new products like the Z1 hip stem is driving market share gains and margin expansion. Despite recent stock performance, analysts believe ZBH is still undervalued by about 1.5% with a fair value of $102.19, driven by its potential for higher earnings and improved margins.
Maridea Wealth Management LLC Purchases New Position in Edwards Lifesciences Corporation $EW
Maridea Wealth Management LLC has acquired a new position in Edwards Lifesciences Corporation, purchasing 22,687 shares valued at approximately $2.05 million during the second quarter. Edwards Lifesciences exceeded analyst expectations with its recent quarterly earnings, reporting $0.78 EPS and $1.74 billion in revenue. The company maintains a "Moderate Buy" consensus rating from analysts, with an average price target of $100.27, suggesting potential upside from its current trading price.
Bank Hapoalim BM Makes New $1.78 Million Investment in Edwards Lifesciences Corporation $EW
Bank Hapoalim BM has invested $1.78 million in Edwards Lifesciences Corporation by purchasing 19,640 shares. This comes as other institutional investors have also adjusted their holdings in the medical research company. Analysts maintain a "Moderate Buy" rating for Edwards Lifesciences, with a consensus target price of $100.27.
Zimmer Biomet - ZIM - Stock Price & News
This article provides a detailed financial overview of Zimmer Biomet (ZIM), a company specializing in orthopedic reconstructive products. It includes stock performance metrics, market capitalization, key financial ratios like revenue, net income, and EPS, along with annual and quarterly growth comparisons. The content also offers company information, industry details, and answers to common investor questions regarding ZIM's stock.
Everett Harris & Co. CA Invests $2.55 Million in Zimmer Biomet Holdings, Inc. $ZBH
Everett Harris & Co. CA recently acquired a new stake of 29,647 shares, valued at approximately $2.55 million, in Zimmer Biomet Holdings, Inc. during the second quarter. Other institutional investors have also adjusted their holdings in ZBH, which currently has 88.89% institutional ownership. Zimmer Biomet recently reported strong Q2 earnings, surpassing analyst expectations, and has declared a quarterly dividend.
Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day
Shares of Zimmer Biomet Holdings Inc. (ZBH) rose 1.08% to $100.65 on Friday, outperforming the S&P 500 Index and Dow Jones Industrial Average, which both saw declines. This marks the third consecutive day of gains for the stock.
Will Zimmer Biomet’s Upgraded 2026 Guidance and Buyback Shift Zimmer Biomet Holdings’ (ZBH) Narrative
Zimmer Biomet Holdings (ZBH) reported strong Q2 2026 results, upgraded its full-year guidance due to better hip and technology segment performance, and completed a $496.84 million share buyback. This move aims to tighten the share count as earnings per share rise and supports the company's investment narrative, which projects $9.3 billion revenue and $1.3 billion earnings by 2029. While the buyback and upgraded guidance reinforce near-term catalysts, risks remain with competitive and regulatory hurdles in advanced robotics.
SYK Stock Gains 3.8% Since March-End: What's Driving the Uptrend?
Stryker (SYK) stock has seen a 3.8% gain since the end of March, outperforming its industry, driven by resilient demand, improved production, and a diversified portfolio. The company's second-quarter results showed strong organic sales and EPS growth, with key factors including the expansion of Mako robotics, increased hospital capital spending, and significant international growth. Despite potential risks like supply disruptions and cybersecurity costs, Stryker's innovation pipeline and competitive advantages position it for continued success.
Handelsbanken Fonder AB Buys 28,130 Shares of Zimmer Biomet Holdings, Inc. $ZBH
Handelsbanken Fonder AB increased its stake in Zimmer Biomet Holdings, Inc. by 22.7% in the second quarter, purchasing an additional 28,130 shares to bring its total to 152,064 shares valued at approximately $13.1 million. Zimmer Biomet exceeded Q2 earnings expectations with $2.07 EPS and $2.18 billion in revenue, maintaining its fiscal 2026 EPS guidance and offering a $0.24 quarterly dividend. Despite mixed analyst sentiment resulting in a "Hold" rating and an average price target of $104.42, institutional investors collectively own 88.89% of the company's stock.
Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day
Shares of Zimmer Biomet Holdings Inc. (ZBH) rose 1.72% to $99.57 on Thursday, outperforming the broader stock market. The S&P 500 Index (SPX) increased by 0.65%, and the Dow Jones Industrial Average (DJIA) gained 0.13%. This marks the stock's second consecutive day of gains.
Zimmer Biomet (ZBH) sees Dodge & Cox disclose 12.5% ownership stake
Dodge & Cox has filed an amended Schedule 13G, revealing a 12.5% beneficial ownership stake in Zimmer Biomet Holdings, Inc. (ZBH), as of June 30, 2026. This represents 24,124,735 shares, with Dodge & Cox holding sole voting power over 22,808,935 shares and sole dispositive power over all 24,124,735 shares. The filing also notes that Dodge & Cox Stock Fund accounts for 8.0% of the outstanding common stock, and clients retain rights to dividends and sale proceeds.
Can Stryker's Q2 Recovery and Guidance Support a Stronger Second Half?
Stryker (SYK) showed strong recovery in Q2 2026 after a cybersecurity disruption, with increased sales, earnings, and improved margins. The company narrowed its full-year guidance, anticipating continued operational execution and conversion of elevated backlog into shipments. While the second half outlook is positive, risks remain from ongoing cyber remediation costs, manufacturing pressures, and a supply disruption in Peripheral Vascular, making execution critical for meeting its targets.
Stryker Up 13.6% in 3 Months as Recovery Gains Strength, What's Next?
Stryker's shares have gained 13.6% in the last three months, outperforming the Zacks Medical sector and S&P 500, driven by a strong operating recovery after a first-quarter cybersecurity disruption. While second-quarter results showed robust organic sales and earnings growth across multiple segments, the company still faces challenges with production ramp-up, backlog reduction, and managing lingering remediation and manufacturing costs. The stock's current valuation is above peers but below its five-year median, suggesting its future performance hinges on strong execution and sustained earnings growth rather than continued rally.
Will Zimmer Biomet’s Upgraded 2026 Guidance and Buyback Shift Zimmer Biomet Holdings’ (ZBH) Narrative
Zimmer Biomet Holdings (ZBH) reported strong Q2 2026 results, including US$2,177 million in sales and US$198.3 million in net income, alongside completing a US$496.84 million share buyback. Management also raised full-year guidance due to robust performance in its hip and technology segments. This move aims to bolster per-share performance and reinforce the company's investment narrative, particularly as it navigates competitive and regulatory challenges in advanced robotics.
NeuroOne Medical Technologies (NASDAQ: NMTC) posts larger loss and flags going concern risk
NeuroOne Medical Technologies (NMTC) reported a deeper net loss of $2.01 million for Q3 2026 and $5.83 million for the nine months ended June 30, 2026, significantly larger than the previous year. The company's cash and cash equivalents dwindled to $2.05 million, leading management to express substantial doubt about its ability to continue as a going concern, with current funds expected to last only until January 2027. Despite an increase in product revenue, the absence of recurring license revenue and higher operating expenses contributed to the rising losses and increased cash burn, further complicated by high customer concentration and ongoing dilution risk from equity financing.
Will Zimmer Biomet’s Upgraded 2026 Guidance and Buyback Shift Zimmer Biomet Holdings’ (ZBH) Narrative
Zimmer Biomet Holdings (ZBH) recently reported strong second-quarter 2026 results, including US$2,177 million in sales and US$198.3 million in net income. The company also completed a significant share repurchase of US$496.84 million and raised its full-year guidance, driven by strong performance in hip and technology segments. These actions are expected to positively influence its investment narrative by tightening share count and supporting per-share performance amidst ongoing competitive and regulatory challenges in advanced robotics.
A2Z Cust2Mate Solutions (NASDAQ:AZ) Upgraded to "Hold" at Zacks Research
Zacks Research has upgraded A2Z Cust2Mate Solutions (NASDAQ:AZ) from "strong sell" to "hold," aligning with the broader analyst consensus and a $15.00 price target. The company recently reported a smaller-than-expected quarterly loss of $0.16 per share and higher-than-anticipated revenue of $5.90 million, while also authorizing a $20 million share buyback program. Despite the upgrade, the stock opened at $6.47 and was trading down 3.4%.
Zimmer Biomet reports strong second quarter financial results
Zimmer Biomet Holdings Inc. announced strong financial results for the second quarter of 2026, with net sales increasing by 4.8% to $2.177 billion and adjusted diluted earnings per share at $2.07. The company is raising its revenue and adjusted EPS guidance for the year due to healthy markets and continued innovation. Key highlights include increased share repurchase expectations, FDA clearance for the ROSA Shoulder System, and recognition as a "Best Healthcare Robotics Solution."
Zimmer Biomet (ZBH): Capital International Investors reports 6.4% ownership stake
Capital International Investors has reported a 6.4% ownership stake in Zimmer Biomet Holdings, Inc. (ZBH), totaling 12,438,366 shares. This passive investment grants them sole voting power over 12,279,364 shares and sole dispositive power over all 12,438,366 shares, as detailed in a Schedule 13G SEC filing. The filing indicates a neutral sentiment and moderate impact, emphasizing that the shares are held for investment purposes rather than control.
Assenagon Asset Management S.A. Buys 97,887 Shares of Zimmer Biomet Holdings, Inc. $ZBH
Assenagon Asset Management S.A. significantly increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the second quarter, purchasing an additional 97,887 shares to bring its total holdings to 102,862 shares valued at $8.855 million. This comes as Zimmer Biomet reported strong quarterly earnings, exceeding analyst expectations with adjusted EPS of $2.07 and revenue of $2.18 billion, a 4.8% year-over-year increase. Despite the positive financial performance, analysts maintain a consensus "Hold" rating on the stock with a price target of $104.42, while the company continues to pay a quarterly dividend of $0.24 per share.
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wall Street analysts are expressing bullish sentiments on several healthcare stocks, specifically Elanco Animal Health (ELAN), Zimmer Biomet Holdings (ZBH), and 10x Genomics (TXG). Analysts from Piper Sandler and Canaccord Genuity have reiterated Buy ratings for these companies, setting price targets that suggest significant upside from current levels. The article highlights analyst consensus and individual analyst performance for each stock.
Can Enovis (ENOV) Narrowing Losses Without Strong Sales Growth Sustain Its Long-Term Strategy?
Enovis Corporation (ENOV) reported Q2 2026 sales of US$582.78 million, a modest increase year-over-year, and significantly reduced its net loss to US$1.19 million from US$36.74 million. The company reaffirmed its 2026 revenue guidance of US$2.31 billion to US$2.37 billion, indicating management's confidence despite only incremental sales growth. The article explores whether Enovis's strategy of narrowing losses without robust sales growth, primarily through acquisitions in medtech and orthopedics, is sustainable for long-term profitability.
NeuroOne(R) Achieves Major Milestone With ISO 13485 Certification
NeuroOne Medical Technologies Corporation has announced it received ISO 13485-2016 certification, an international standard for Quality Management Systems in the Medical Device Industry. This certification allows NeuroOne to pursue international marketing opportunities for its Evo® Cortical and Evo® sEEG Electrodes, and the OneRF® Brain Ablation System, opening doors for international revenue growth. The company plans to work with distribution partner Zimmer Biomet and explore independent partnerships for market entry.
Handelsbanken Fonder AB Has $139.42 Million Holdings in Edwards Lifesciences Corporation $EW
Handelsbanken Fonder AB increased its stake in Edwards Lifesciences Corporation by 22% in the second quarter, bringing its total holdings to approximately $139.4 million. Edwards Lifesciences reported strong quarterly earnings of $0.78 per share, exceeding estimates, with a 13.6% year-over-year revenue increase. The company has a "Moderate Buy" consensus rating from analysts with an average price target of $100.27.
Zimmer Biomet Holdings Inc. stock outperforms competitors on strong trading day
Zimmer Biomet Holdings Inc. (ZBH) saw its stock advance by 1.27% to $97.78 on Monday, outperforming the broader market which experienced a dismal trading session. This rise broke a two-day losing streak for the company's shares. The S&P 500 Index and Dow Jones Industrial Average both fell, by 0.06% and 0.11% respectively.
DePuy Synthes to establish center in India as J&J reportedly looks to sell the business
DePuy Synthes, a Johnson & Johnson Medtech business, plans to establish a new Global Capability Centre (GCC) in Bangalore, India, to enhance clinical innovation and operational excellence. This move comes as India is projected to be the fastest-growing regional market for orthopedic devices, reaching $3.03 billion by 2030. The establishment of the center, which will host about 500 professionals, coincides with reports that Johnson & Johnson is working to sell its DePuy Synthes Orthopaedics business, potentially valued over $20 billion.
Zimmer Biomet (NYSE:ZBH) Price Target Raised to $100.00
Canaccord Genuity raised Zimmer Biomet's (NYSE:ZBH) price target from $83.00 to $100.00 while maintaining a "hold" rating, suggesting a 3.59% upside. The medical equipment provider recently reported strong quarterly earnings, beating EPS estimates by $0.06 and achieving a 4.8% year-over-year revenue increase. Analysts, on average, rate the stock as "Hold" with an average price target of $104.42.
Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Theravance Biopharma, Inc. announced its Q2 2026 financial results, highlighted by an 11% year-over-year increase in YUPELRI collaboration revenue and a significant 35% reduction in operating expenses due to restructuring. The company also confirmed its pending acquisition by Zymeworks for $17.00 per share cash plus a CVR, expected to close in the second half of 2026. Theravance Biopharma remains confident in achieving a $100 million milestone payment from Royalty Pharma based on TRELEGY net sales.
Price to earnings forward of Zimmer Biomet Holdings, Inc. – NYSE:ZBH
This article provides the "Price to earnings forward" value for Zimmer Biomet Holdings, Inc. (NYSE: ZBH). The information is presented within a TradingView context, indicating financial data and analysis for the company. The page focuses on financial metrics and market data for ZBH.
Price to earnings forward of Zimmer Biomet Holdings, Inc. – BX:ZIM
The article presents the "Price to earnings forward" value for Zimmer Biomet Holdings, Inc. (BX:ZIM) on TradingView. It appears to be a financial data point for the company, indicating its valuation based on future earnings expectations. The page also includes various navigation and information sections typical of a financial data platform.
Agape ATP Corp (ATPC) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Agape ATP Corp (ATPC), focusing on future EPS and revenue growth estimates. It highlights the stock's current trading information, including its price and market capitalization, and lists key financial metrics like Net Profit and EBIT. The page also includes a peer comparison for ATPC within the Healthcare Equipment & Supplies sector.
